Kalvista Pharmaceuticals Stock Price To Earnings To Growth

KALV Stock

USD 10.06 0.03 0.30%

Kalvista Pharmaceuticals fundamentals help investors to digest information that contributes to Kalvista Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Kalvista Stock. The fundamental analysis module provides a way to measure Kalvista Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kalvista Pharmaceuticals stock.

Short Long Term Debt Total Total Assets

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Kalvista Pharmaceuticals Company Price To Earnings To Growth Analysis

Kalvista Pharmaceuticals' PEG Ratio indicates the potential value of an equity instrument and is calculated by dividing Price to Earnings (P/E) ratio into earnings growth rate. Most analysts and investors prefer this measure to a Price to Earnings (P/E) ratio because it incorporates the future growth of a firm. The low PEG ratio usually implies that an equity instrument is undervalued; whereas PEG of 1 may indicate that an equity is reasonably priced under given expectations of future growth.

PEG Ratio

PE Ratio

EPS Growth

More About Price To Earnings To Growth | All Equity Analysis

Kalvista Price To Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for Kalvista Pharmaceuticals is extremely important. It helps to project a fair market value of Kalvista Stock properly, considering its historical fundamentals such as Price To Earnings To Growth. Since Kalvista Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Kalvista Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Kalvista Pharmaceuticals' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Short Term Debt	Common Stock	Long Term Debt	Long Term Debt Total	Capital Surpluse	Property Plant Equipment	Net Tangible Assets	Net Receivables	Deferred Long Term Liab	Short Long Term Debt	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.99	0.42	-0.62	-0.82	0.75	-0.21	1.0	-0.52	0.8	0.37	0.73	0.78	0.66	0.86	0.79	-0.09	0.19	0.94	0.94	0.7
Total Stockholder Equity	0.99		0.46	-0.62	-0.8	0.74	-0.34	0.99	-0.55	0.82	0.34	0.78	0.78	0.68	0.87	0.79	-0.12	0.15	0.94	0.94	0.68
Current Deferred Revenue	0.42	0.46		-0.79	-0.34	0.37	-0.38	0.43	-0.82	0.44	-0.59	0.12	0.27	0.51	0.48	0.51	0.47	-0.75	0.36	0.37	0.31
Net Debt	-0.62	-0.62	-0.79		0.43	-0.39	0.21	-0.62	0.8	-0.57	0.27	-0.3	-0.59	-0.72	-0.66	-0.59	-0.47	0.47	-0.51	-0.53	-0.38
Retained Earnings	-0.82	-0.8	-0.34	0.43		-0.96	0.06	-0.82	0.32	-0.84	-0.32	-0.6	-0.57	-0.49	-0.53	-0.7	0.11	-0.17	-0.76	-0.75	-0.9
Accounts Payable	0.75	0.74	0.37	-0.39	-0.96		-0.08	0.75	-0.35	0.83	0.24	0.58	0.39	0.43	0.4	0.63	-0.08	0.09	0.68	0.67	0.88
Total Liab	-0.21	-0.34	-0.38	0.21	0.06	-0.08		-0.21	0.35	-0.39	0.14	-0.54	-0.17	-0.27	-0.3	-0.26	0.25	0.21	-0.24	-0.23	-0.07
Total Current Assets	1.0	0.99	0.43	-0.62	-0.82	0.75	-0.21		-0.53	0.8	0.37	0.73	0.78	0.66	0.86	0.78	-0.08	0.18	0.94	0.94	0.69
Short Term Debt	-0.52	-0.55	-0.82	0.8	0.32	-0.35	0.35	-0.53		-0.55	0.2	-0.34	-0.45	-0.67	-0.56	-0.66	-0.3	0.45	-0.38	-0.4	-0.2
Common Stock	0.8	0.82	0.44	-0.57	-0.84	0.83	-0.39	0.8	-0.55		0.26	0.74	0.57	0.62	0.55	0.68	-0.11	0.05	0.77	0.77	0.83
Long Term Debt	0.37	0.34	-0.59	0.27	-0.32	0.24	0.14	0.37	0.2	0.26		0.59	0.43	0.23	0.28	0.34	-0.6	0.96	0.37	0.35	0.2
Long Term Debt Total	0.73	0.78	0.12	-0.3	-0.6	0.58	-0.54	0.73	-0.34	0.74	0.59		0.61	0.69	0.63	0.74	-0.31	0.45	0.66	0.66	0.45
Capital Surpluse	0.78	0.78	0.27	-0.59	-0.57	0.39	-0.17	0.78	-0.45	0.57	0.43	0.61		0.77	0.9	0.78	-0.14	0.27	0.74	0.74	0.43
Property Plant Equipment	0.66	0.68	0.51	-0.72	-0.49	0.43	-0.27	0.66	-0.67	0.62	0.23	0.69	0.77		0.77	0.88	0.2	0.05	0.58	0.59	0.36
Net Tangible Assets	0.86	0.87	0.48	-0.66	-0.53	0.4	-0.3	0.86	-0.56	0.55	0.28	0.63	0.9	0.77		0.79	-0.07	0.11	0.84	0.85	0.42
Net Receivables	0.79	0.79	0.51	-0.59	-0.7	0.63	-0.26	0.78	-0.66	0.68	0.34	0.74	0.78	0.88	0.79		0.03	0.14	0.67	0.67	0.49
Deferred Long Term Liab	-0.09	-0.12	0.47	-0.47	0.11	-0.08	0.25	-0.08	-0.3	-0.11	-0.6	-0.31	-0.14	0.2	-0.07	0.03		-0.63	-0.23	-0.2	-0.16
Short Long Term Debt	0.19	0.15	-0.75	0.47	-0.17	0.09	0.21	0.18	0.45	0.05	0.96	0.45	0.27	0.05	0.11	0.14	-0.63		0.22	0.2	0.08
Net Invested Capital	0.94	0.94	0.36	-0.51	-0.76	0.68	-0.24	0.94	-0.38	0.77	0.37	0.66	0.74	0.58	0.84	0.67	-0.23	0.22		1.0	0.77
Net Working Capital	0.94	0.94	0.37	-0.53	-0.75	0.67	-0.23	0.94	-0.4	0.77	0.35	0.66	0.74	0.59	0.85	0.67	-0.2	0.2	1.0		0.76
Capital Stock	0.7	0.68	0.31	-0.38	-0.9	0.88	-0.07	0.69	-0.2	0.83	0.2	0.45	0.43	0.36	0.42	0.49	-0.16	0.08	0.77	0.76

Click cells to compare fundamentals

Generally speaking, PEG ratio is a 'quick and dirty' way to measure how the current price of a firm's stock relates to its earnings and growth rate. The main benefit of using PEG ratio is that investors can compare the relative valuations of companies within different industries without analyzing their P/E ratios.

Competition

Predict Kalvista Pharmaceuticals

Kalvista Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

(0.12)

At this time, Kalvista Pharmaceuticals' Price Earnings To Growth Ratio is fairly stable compared to the past year.

Based on the latest financial disclosure, Kalvista Pharmaceuticals has a Price To Earnings To Growth of 0.0 times. This is 100.0% lower than that of the Biotechnology sector and 100.0% lower than that of the Health Care industry. The price to earnings to growth for all United States stocks is 100.0% higher than that of the company.

Kalvista Price To Earnings To Growth Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kalvista Pharmaceuticals' direct or indirect competition against its Price To Earnings To Growth to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kalvista Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Kalvista Pharmaceuticals by comparing valuation metrics of similar companies.

Kalvista Pharmaceuticals is currently under evaluation in price to earnings to growth category among its peers.

Kalvista Pharmaceuticals ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Kalvista Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Kalvista Pharmaceuticals' managers, analysts, and investors.

Environmental

Governance

Social

Kalvista Fundamentals

	Return On Equity	-0.91
	Return On Asset	-0.54
	Current Valuation	328.56 M
	Shares Outstanding	49.22 M
	Shares Owned By Insiders	1.34 %
	Shares Owned By Institutions	98.66 %
	Number Of Shares Shorted	7.37 M
	Price To Earning	(2.82) X
	Price To Book	2.87 X
	Price To Sales	107.42 X
	Gross Profit	(80.28 M)
	EBITDA	(134.28 M)
	Net Income	(126.64 M)
	Cash And Equivalents	142.08 M
	Cash Per Share	5.78 X
	Total Debt	7.32 M
	Debt To Equity	0.05 %
	Current Ratio	17.51 X
	Book Value Per Share	4.01 X
	Cash Flow From Operations	(89.23 M)
	Short Ratio	23.75 X
	Earnings Per Share	(3.57) X
	Target Price	29.17
	Number Of Employees	150
	Beta	0.91
	Market Capitalization	496.58 M
	Total Asset	235.4 M
	Retained Earnings	(469.73 M)
	Working Capital	202.88 M
	Current Asset	54.95 M
	Current Liabilities	4.27 M
	Net Asset	235.4 M

About Kalvista Pharmaceuticals Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Kalvista Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kalvista Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kalvista Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Kalvista Stock Analysis

When running Kalvista Pharmaceuticals' price analysis, check to measure Kalvista Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kalvista Pharmaceuticals is operating at the current time. Most of Kalvista Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kalvista Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kalvista Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kalvista Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC